Filing summary
Entity and period mismatch: The supplied filing is OvaScience, Inc.’s Form 10-K for the fiscal year ended December 31, 2012, filed February 25, 2013. It is not a Tempest Therapeutics filing, and it reports annual results rather than a standalone 2012 Q4 period.
Business context
OvaScience was an early-stage life-sciences company developing infertility treatments based on egg precursor cells. Its lead candidate, AUGMENT, was designed to add mitochondria from a patient’s own egg precursor cells to her egg during IVF. OvaTure, in preclinical development, aimed to mature egg precursor cells into fertilizable eggs. The company had no commercial products or revenue.
Financial results and liquidity
| Metric | FY 2012 | Prior period / year-end comparison |
|---|---|---|
| Revenue | $0 | $0 since inception |
| Research and development expense | $6.323 million | $1.170 million from inception (April 5, 2011) to December 31, 2011 |
| General and administrative expense | $7.206 million | $1.454 million for the 2011 inception period |
| Net loss | $13.510 million | $2.624 million for the 2011 inception period |
| Operating cash use | $11.156 million | $1.560 million for the 2011 inception period |
| Cash, cash equivalents and marketable securities | $31.391 million at year-end | $4.541 million at December 31, 2011 |
The 2011 comparison covers approximately nine months and is not a full-year comparable period. FY 2012 operating expenses totaled $13.529 million; interest income was $19,000. The filing reports no debt financing or interest-bearing borrowings. Year-end current liabilities were $2.086 million, total liabilities were $2.093 million, and stockholders’ equity was $30.721 million. No conventional gross-profit or operating margin is meaningful because the company had no revenue.
Financing cash flow was $39.031 million in 2012, primarily from the Series B preferred-stock financing and a common-stock placement. Investing cash use was $17.640 million, including $16.698 million of short-term investment purchases and $849,000 of property and equipment. Management expected year-end resources to fund operations and capital needs at least through the end of 2013, assuming no product revenue; it said additional funding would be required after 2013.
Changes, outlook and key risks
- R&D expense increased by $5.153 million, or 440%, versus the 2011 inception period; G&A increased by $5.752 million, or 396%. The periods differ in length. G&A included about $1.410 million of Form 10-related legal and accounting costs that management did not expect to recur.
- In late 2012, OvaScience began an open-label AUGMENT study planned for up to 40 women aged 38–42 with prior IVF failures. It had no formal control arm; management expected preliminary pregnancy-rate data in late 2013. The study’s primary objective was safety, with efficacy measures secondary.
- Assuming positive study results, the company planned to pursue AUGMENT commercialization in the United States and selected international markets in the second half of 2014. It also planned an international human study beginning in the first half of 2014. These were plans, not assured outcomes.
- OvaTure was in preclinical development and expected to require regulatory approval in the United States and EU. The company was also considering IVF culture media and egg precursor-cell banking.
- A major uncertainty was whether FDA would accept management’s view that AUGMENT qualified as a lower-risk “361 HCT/P” without premarket approval. The FDA had contacted the company about the study and related matters, including the regulatory classification. If FDA disagreed, additional studies, an IND and potentially an NDA or BLA could materially increase cost and delay or prevent commercialization. International rules could differ as well.
- Management expected continued losses and rising expenses. Key risks included unproven science and human safety/efficacy, study enrollment and results, regulatory classification, reliance on third-party manufacturing and research providers, manufacturing scale and cost, limited reimbursement, patent and licensing risks, competition, and the need for additional capital. The filing states that existing funding was not committed beyond the stated runway.
- The independent auditor issued an unqualified opinion on the financial statements. The auditor did not express an opinion on internal control over financial reporting; management said disclosure controls were effective as of year-end.
Important facts for investors to verify
- Confirm the filing belongs to OvaScience, not Tempest Therapeutics, and verify the intended issuer and reporting period.
- Check subsequent AUGMENT study enrollment, safety and efficacy results, and whether any findings support the planned launch timeline.
- Verify FDA’s and relevant non-U.S. regulators’ classification and requirements for AUGMENT; the company’s 361 HCT/P position was its own view, not an established approval.
- Assess actual cash burn, financing needs and funding availability against the stated end-of-2013 runway, as well as the cost and scalability of third-party manufacturing.
- Review the latest cash and investment balances, share count and dilution exposure; the 2012 preferred shares converted to common stock, and further financing could dilute shareholders.